Close menu

December 20th, 2021 | 13:56 CET

Alibaba, Ayurcann, Rock Tech Lithium - Portfolio boosters for 2022

  • Cannabis
Photo credits:

The stock market year 2021 is slowly coming to an end, and many investors have cleaned up their portfolios. The question now is, which trends and stocks will ignite in the coming year! The Corona pandemic has come back into focus with the Omicron variant. So this vexed topic will continue to occupy us in the coming year. Profiteers from this are e-commerce companies like Alibaba. With the new traffic light government, the legalization of cannabis is being tackled. Efforts are increasing worldwide to make the consumption of hemp no longer a criminal offense. Well-positioned in this area is Ayurcann. An exciting third market is lithium, which is essential for the production of electric vehicles. Rock Tech Lithium is excellently positioned in this area.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Alibaba - Turnaround in sight?

    Alibaba has not had a good year from a shareholder perspective. On the one hand, because of the regulation by the Chinese government, on the other hand, the annual forecast was cut, and the margins became smaller. When Didi announced its withdrawal from the New York Stock Exchange, the fear of delisting also went around among Alibaba shareholders. There are always accusations that the Company is not closely connected to social media, unlike WeChat and TikTok. Despite all the problems, what makes the stock a promising candidate for 2022?

    It has expanded its social media activities with DingTalk, reaching more than 500 million users. The Company is in a better economic position than all its competitors and already has competitive advantages in global e-commerce. If you look at the sales growth in combination with the margin, you quickly see that no one can keep up here. Amazon is growing less and has a 15% less margin. Pinduoduo and Bilibili are growing faster but making losses. Tencent has more margin but is growing 14% less. Due to greater competition within China, exponential growth has slowed.

    While e-commerce margins are declining, the profitability of other businesses is increasing significantly almost everywhere. The main opportunities are in the global market, and Alibaba, via AliExpress, knows how to connect international customers directly with Chinese manufacturers. In Eastern Europe in particular, they are well ahead of Amazon and are able to gain market share. It has also been able to gain market share in Western Europe, whereas its big competitor is stagnating. The specter of delisting should not worry investors too much. Alibaba ADR shares can be exchanged for corresponding shares in Hong Kong. That would likely weigh on the share price only in the short term.

    Ayurcann - Growing fast with high margins

    Canada-based Ayurcann Holdings Corp. offers licensed cannabis producers the opportunity to have their raw material refined post-harvest through the Company's offered outsourcing solutions. Services offered range from extraction and refining to bulk distillate oil sales, formulation and white-label manufacturing, fulfillment and distribution, and custom packaging solutions and inventory management services. Medical cannabis is also offered, such as tinctures, vapes for vaporizers, topicals, and creams. Canadian customers can purchase these products through the Ayurcann Marketplace, where they receive advice from expert staff.

    That cannabis is a growth market is shown by the annual figures. The fiscal year ended June 30, and sales increased by CAD 7 million or 1,149% over the previous year. Operating income was over CAD 2 million. An increase of 440%. On November 29, the Company released its third-quarter numbers and again, further growth can be seen. Revenues climbed 137% YOY to CAD 1.9 million. Profit was CAS 931,000, up 137%. The margin of 49% shows the attractiveness of the business. In addition, the expansion of production capacity at the Pickering Plant was completed. The Company can now process 300,000kg of biomass and expand filling up to 3 million packs.

    The Company has an international customer base that owns well-known cannabis brands - ranging from Xplor in the UK to Innocan Pharma from Israel to Green Bee Botanicals and Her Highness from the US. In the US, some states have legalized cannabis. The stock was previously listed on the CSE in Canada and Frankfurt. Since December 16, Americans have also been able to buy the shares on the OTCQB, the leading marketplace for startups in the US. Despite all the good news, the share is trading at just CAD 0.165, well below its high for the year at CAD 0.75. The market capitalization of CAD 20 million is significantly lower than that of the competitors and offers some catch-up potential.

    Rock Tech Lithium - The lithium market will continue to boom

    The hype around electric vehicles was one of the hot topics in 2021 and will remain so in the future. The switch from internal combustion engines to zero-emission drives creates a huge demand for lithium, cobalt and graphite needed to produce e-batteries. The Canadian Company Rock Tech Lithium wants to extract lithium from its mine in an environmentally friendly way and then convert it into lithium hydroxide using a converter. The first converter is to be built in Guben and start operation in 2024.

    One converter can supply around 500,000 electric cars with lithium hydroxide. Since the raw materials are finite, the Company has already looked into recycling the old e-batteries. That would cover the entire value chain and make the Company independent of lithium mining in the long term. As soon as the first lithium hydroxide factory is up and running, four more are to be built in Europe by 2029. As a result, according to management's plans, the Company is likely to capture about 30% of the European market.

    While the new plant is being prepared, pilot studies are underway to produce high-quality, battery-grade lithium hydroxide. The purity level must be more than 99.5%. In November, the trials were completed successfully. On December 3, the Company published the results of the technical study of the converter conducted by Wave International Pty. The plant will pay for itself within 64 months. Currently trading at CAD 6.02, the share has consolidated significantly after its recent rally and offers a first entry opportunity here at support.

    All three companies have significant upside potential. Unlike other e-commerce companies, Alibaba is trading near a multi-year low and is fundamentally cheap. Ayurcann is in the black, has good margins and is growing strongly. If you want to bet on cannabis, this is the place to be. Rock Tech Lithium offers attractive opportunities to enter the lithium market, which is set to become increasingly important in the coming years.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET

    Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Cannabis
    • Cancer

    Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.


    Commented by Armin Schulz on February 8th, 2023 | 11:49 CET

    BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?

    • Biotechnology
    • Cancer
    • vaccine
    • Cannabis

    The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.


    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?